Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for YARW.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 0.788M
March 31, 2026 0.817M
December 31, 2025 2.977M
September 30, 2025 5.256M
June 30, 2025 4.881M
March 31, 2025 6.124M
December 31, 2024 9.684M
September 30, 2024 10.25M
June 30, 2024 7.306M
March 31, 2024 3.708M
December 31, 2023 3.023M
September 30, 2023 3.318M
June 30, 2023 7.233M
March 31, 2023 2.734M
December 31, 2022 4.279M
September 30, 2022 5.546M
June 30, 2022 4.108M
March 31, 2022 4.452M
December 31, 2021 4.324M
September 30, 2021 5.917M
Date Value
June 30, 2021 5.048M
March 31, 2021 4.255M
December 31, 2020 7.838M
September 30, 2020 6.623M
June 30, 2020 13.12M
March 31, 2020 15.95M
December 31, 2019 15.35M
September 30, 2019 12.45M
June 30, 2019 12.56M
March 31, 2019 10.85M
December 31, 2018 15.08M
September 30, 2018 10.67M
June 30, 2018 16.23M
March 31, 2018 11.02M
December 31, 2017 10.55M
September 30, 2017 8.009M
June 30, 2017 5.46M
March 31, 2017 4.992M
December 31, 2016 4.077M
September 30, 2016 2.852M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Ironwood Pharmaceuticals, Inc. 21.96M
Theriva Biologics, Inc. 1.268M
Nkarta, Inc. 26.31M
Unicycive Therapeutics, Inc. 2.788M
OnKure Therapeutics, Inc. 12.51M